iSpecimen
ISPC
12 hedge funds and large institutions have $597K invested in iSpecimen in 2023 Q2 according to their latest regulatory filings, with 2 funds opening new positions, increasing their positions, 0 reducing their positions, and 3 closing their positions.
0.88% less ownership
Funds ownership: 5.5% → 4.62% (-0.88%)
8% less funds holding
Funds holding: 13 → 12 (-1)
33% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 3
64% less capital inflows, than outflows
Capital inflows: $56K | Capital outflows: $156K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$33.8K |
| 2 |
Renaissance Technologies
New York
|
+$22.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bleichroeder LP
New York
|
-$88.2K |
| 2 |
Teton Advisors
Rye,
New York
|
-$50.9K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$17.3K |
ISPC Hedge Fund Activity: Q2 2023 in Review
12 of the 6,389 institutional investors tracked by Wall St. Rank reported a position in iSpecimen (ISPC) for Q2 2023, worth a combined $597K — down 10% from $665K a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of ISPC and 2 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $33.8K. The largest seller was Bleichroeder LP, exiting entirely with an estimated $88.2K sold.
- 12 institutional investors held iSpecimen (ISPC) as of Q2 2023, down from 13 in Q1 2023.
- Funds reported $597K of iSpecimen stock for Q2 2023, down 10% quarter-over-quarter.
- 2 funds opened new iSpecimen positions in Q2 2023 and 3 closed out, a net change of -1 holder.
- The largest iSpecimen buyer in Q2 2023 was Citadel Advisors, an estimated $33.8K added.
- The largest iSpecimen seller in Q2 2023 was Bleichroeder LP, an estimated $88.2K sold.
Based on aggregated 13F filings for Q2 2023.